A Concise Approach for Producing Optically Pure Carboxylic Acid Segments for the Synthesis of Bicyclic Depsipeptide Histone Deacetylase Inhibitors

Dedicated to Professor Tohru Fukuyama, Nagoya University, Japan on his 70^th birthday

Abstract

Optically pure carboxylic acid segments, which are common key intermediates for the synthesis of naturally occurring bicyclic depsipeptide histone deacetylase inhibitors, have been produced efficiently. The method features the chromatographic separation of two diastereomers, which were formed by direct amide condensation of racemic (3RS,4E)-3-hydroxy-7-mercaptohept-4-enoic acid (rac-Hmh) with chiral amino acids. This approach offers a reliable and practical method for producing optically pure carboxylic acid segments, which can facilitate easier access to important anticancer agents derived from them.

Key words

synthetic intermediate - histone deacetylase inhibitor - ­natural product - bicyclic depsipeptide - total synthesis

• References

• 1a Van der Molen KM, McCulloch W, Pearce CJ, Oberlies NH. J. Antibiot. 2011; 64: 525
• 1b Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE. Expert Rev. Anticancer Ther. 2010; 10: 997
• 2a Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M. J. Antibiot. 1994; 47: 301
• 2b Shigematsu N, Ueda H, Takase S, Tanaka H. J. Antibiot. 1994; 47: 311
• 2c Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K. J. Antibiot. 1994; 47: 315
• 3 Furumai R, Matsuyama A, Kobashi N, Lee K.-H, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S. Cancer Res. 2002; 62: 4916
• 4 Okuhara M, Goto T, Fujita T, Hori Y, Ueda H. Jpn. Kokai Tokkyo Koho JP 3141296, 1991

Spiruchostatins A (3) and B (4), see:
• 5a Masuoka Y, Nagai A, Shin-ya K, Furihata K, Nagai K, Suzuki K, Hayakawa Y, Seto H. Tetrahedron Lett. 2001; 42: 41

Spiruchostatin C (5), see:
• 5b Shindo N, Terada A, Mori M, Amino N, Hayata K, Nagai K, Hayakawa Y, Shin-ya K, Masuoka Y. (Yamanouchi Pharmaceutical Co. Ltd.) Jpn. Kokai Tokkyo Koho JP 348340A, 2001

Spiruchostatin D (6), see:
• 5c Nagai K, Taniguchi M, Shindo N, Terada Y, Mori M, Amino N, Suzumura K, Takahashi I, Amase M. (Yamanouchi Pharmaceutical Co. Ltd.) PCT WO 20460 A1, 2004
• 6 Spiruchostatin A (3, registered as both YM753 and OBP-801) is currently in human clinical trials (phase I) as a potential anticancer therapy in the United States.
• 7 Biggins JB, Gleber CD, Brady SF. Org. Lett. 2011; 13: 1536
• 8a Wang C, Flemming CJ, Cheng Y.-Q. Med. Chem. Commun. 2012; 3: 976
• 8b Wang C, Henkes LM, Doughty LB, He M, Wang D, Meyer-Almes FJ, Cheng Y.-Q. J. Nat. Prod. 2011; 74: 2031

Total synthesis of FK228 (1, romidepsin):
• 9a Narita K, Kikuchi T, Watanabe K, Takizawa T, Yamori T, Yoshida M, Katoh T. Chem. Eur. J. 2009; 15: 11174
• 9b Greshock TJ, Johns DM, Noguchi Y, Williams RM. Org. Lett. 2008; 10: 613
• 9c Wen S, Packham G, Ganesan A. J. Org. Chem. 2008; 73: 9353
• 9d Li KW, Wu J, Xing W, Simon JA. J. Am. Chem. Soc. 1996; 118: 7237

Total synthesis of FR901375 (2):
• 10a Narita K, Katoh Y, Ojima K, Dan S, Yamori T, Ito A, Yoshida M, Katoh T. Eur. J. Org. Chem. 2016; 5667
• 10b Chen Y, Gambs C, Abe Y, Wentworth PJr, Janda KD. J. Org. Chem. 2003; 68: 8902

Total synthesis of spiruchostatin A (3):
• 11a Yoshida M, Sasahara K, Doi T. Tetrahedron 2015; 71: 7647
• 11b Calandra NA, Cheng YL, Kocak KA, Miller JS. Org. Lett. 2009; 11: 1971
• 11c Takizawa T, Watanabe K, Narita K, Kudo K, Oguchi T, Abe H, Katoh T. Heterocycles 2008; 76: 275
• 11d Doi T, Iijima Y, Shin-ya K, Ganesan A, Takahashi T. Tetrahedron Lett. 2006; 47: 1177
• 11e Yurek-George A, Habens F, Brimmell M, Packham G, Ganesan A. J. Am. Chem. Soc. 2004; 126: 1030

Total synthesis of spiruchostatin B (4):
• 12a Fuse S, Okada K, Iijima Y, Munakata A, Machida K, Takahashi T, Takagi M, Shin-ya K, Doi T. Org. Biomol. Chem. 2011; 9: 3825
• 12b Takizawa T, Watanabe K, Narita K, Kudo K, Oguchi T, Abe H, Katoh T. Chem. Commun. 2008; 1677
• 13 Total synthesis of spiruchostatins C (5) and D (6): Narita K, Fukui Y, Sano Y, Yamori T, Ito A, Yoshida M, Katoh T. Eur. J. Med. Chem. 2013; 60: 295

Total synthesis of burkholdacs A (7, thailandepsin C) and/or B (8, thailandepsin A):
• 14a Fukui Y, Narita K, Dan S, Yamori T, Ito A, Yoshida M, Katoh T. Eur. J. Med. Chem. 2014; 76: 301
• 14b Liu JY, Ma X, Liu Y, Wang Z, Kwong S, Ren Q, Tang S, Meng Y, Xu Z, Ye T. Synlett 2012; 23: 783
• 14c Benelkebir H, Donlevy AM, Packham G, Ganesan A. Org. Lett. 2011; 13: 6334

Total synthesis of thailandepsin B (10):
• 15a Narita K, Katoh T. Chem. Pharm. Bull. 2016; 64: 913
• 15b Cheng Y.-Q, Yang S, Wang P. (ChinAn PharmaTech Wuhan Co., Ltd.) PCT WO 131355A1, 2015
• 16a Being different from the case of the syntheses of FK228 (1) and FR901375 (2), the enantiomer of 21 (ent-21) is necessary for the key intermediate of spiruchostatins 3–6, burkholdacs 7and 8, and thailandepsins 7–12. This is because, in those syntheses, typical macrolactonization methods (e.g., the Shiina method and the Yamaguchi method), which proceed via retention of the stereochemistry at the hydroxy group, were employed instead of the Mitsunobu macrolactonization method.
• 16b For the Shiina method, see: Shiina I, Katoh T, Nagai S, Hashizume M. Chem. Rec. 2009; 9: 305
• 16c For the Yamaguchi method, see: Inanaga J, Hirata K, Saeki H, Katsuki T, Yamaguchi M. Bull. Chem. Soc. Jpn. 1979; 52: 1989
• 16d For the Mitsunobu method, see: Mitsunobu O. Synthesis 1981; 1
• 17 We also could not reproduce the Simon’s asymmetric aldol reaction (i.e., Scheme 2, eq. 1, 27 + 28 → 29, 95% yield with 98% ee). Our several follow-up experiments resulted in poor yield (~20%) of 29 with 95–98% ee.
• 18a Based on the present study, industrial synthesis of FK-A11, which is a novel bicyclic depsipeptide histone deacetylase/phosphatidylinositol 3-kinase dual inhibitor under preclinical trials, has been carried out at Hamari Chemicals, Ltd. (Osaka, Japan).
• 18b cf. Saijo K, Imai H, Chikamatsu S, Narita K, Katoh T, Ishioka C. Cancer Sci. 2017; 108: 1469
• 19 Sayar N, Narita K, Katoh T. Synthesis 2019; 51 in press, DOI: 10.1055/s-0037-1611707.